R&D channel feed

Gavi an­nounces $1.8B for vac­cine ac­cess, pan­dem­ic pre­pared­ness ef­forts in Africa

Last year
Pharma
Manufacturing

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Last year
Cell/Gene Tx
In Focus

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Last year
Startups
Cell/Gene Tx

Sol­id tu­mor biotech’s poly­mer nanopar­ti­cle-drug con­ju­gate clears ear­ly-stage hur­dle, spark­ing PhII plans

Last year

Allen In­sti­tute and Chan Zucker­berg Ini­tia­tive launch re­search cen­ter to probe mys­ter­ies of the cell

Last year

Sanofi CEO Paul Hud­son pitch­es 12 block­busters in a bid to con­vince in­vestors on boost­ing R&D spend

Last year
Pharma

Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Last year

Up­dat­ed: 89bio prices $150M pub­lic of­fer­ing for PhI­II de­vel­op­ment of NASH drug

Last year
Financing

Re­gen­eron heads to­ward FDA fil­ing for mul­ti­ple myelo­ma bis­pe­cif­ic, set­ting up show­down with J&J, Pfiz­er: #ASH23

Last year

Brain cell at­las for Alzheimer's dis­ease is the tar­get of NI­H's new col­lab­o­ra­tion with 10x Ge­nomics

Last year

Wave makes $100M pub­lic of­fer­ing af­ter dos­ing first sub­jects with GSK-part­nered RNA edit­ing drug

Last year
Financing

FDA asks for more da­ta from Opti­nose, ex­tends re­view time for nasal spray

Last year
FDA+

Sy­ros' stock up al­most 30% af­ter pos­i­tive ear­ly PhII da­ta for blood can­cer drug

Last year

Seagen po­si­tions Tukysa com­bo as op­tion for breast can­cer pa­tients with brain metas­tases

Last year

Ger­man biotech’s ef­forts to re­vive obe­si­ty tar­get for sol­id tu­mors yield pos­i­tive PhI­Ia re­sults

Last year

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

Last year
AI
In Focus

Phar­varis soars on mid-stage da­ta for se­vere swelling con­di­tion, rais­es $300M

Last year
Financing

IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

Last year
People

Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

Last year

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

Last year
Pharma

Bio­gen col­lab­o­ra­tor Neu­roSense shares sec­ondary PhI­Ib da­ta for its ALS treat­ment

Last year

Scoop: In­fec­tious dis­ease biotech eyes $25M Se­ries A to ad­vance an­ti­body for chron­ic lung in­fec­tion

Last year
Financing

Lil­ly’s Verzenio just miss­es the mark on over­all sur­vival in PhI­II breast can­cer study

Last year

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Last year
Pharma
First page Previous page 58596061626364 Next page Last page
A service from the Financial Times